【人物档案】 姚晨姣，省政协委员，中南大学湘雅三医院全科医学科主任兼老年病科主任。 "让百姓在家门口看上病、看好病！"省政协委员姚晨姣用近30年医者初心与扎实履职，深耕紧密型县域 医共体建设与全科医学发展，在健康湖南的画卷上，勾勒出民生为本的温暖底色。2025年，姚晨姣当选 中华医学会全科医学分会常务委员，成为湖南首位获此殊荣的专家。 姚晨姣始终扎根基层找症结、谋对策。2025年，她随省政协民主监督调研组深入张家界、常德等地，既 见证了湖南医共体建设的阶段性成效，也直面基层人才匮乏、患者"向上挤"等痛点。"打通信息壁垒， 落实人财物政策，让县乡村医疗拧成一股绳！"她在省政协民主监督协商会上的建言，得到省卫健委、 省医保局等部门积极回应。 针对全科医学科覆盖率低、信息化滞后等问题，姚晨姣接连献策：搭建跨机构健康数据共享平台，打 破"信息孤岛"；建立全科医生远程培训系统，为基层赋能……如今，多学科协作诊疗在基层落地，娄底 慢病患者通过智能穿戴设备告别奔波复诊，"数据多跑路，患者少跑腿"成为生动现实。 ■三湘都市报全媒体记者 王智芳 通讯员 田翎君 ...

慢性肾脏病是一种进展性疾病，肾脏功能会逐渐减退。而饮食作为影响肾脏负担的重要因素，一直是患 者和家属关注的焦点。很多人会问，慢性肾脏病患者在饮食上需要"忌口"吗？答案是肯定的，但"忌 口"并非盲目禁食，而是要根据病情和肾脏功能，科学调整饮食结构。合理的饮食能减轻肾脏负担，延 缓病情进展。下面就为大家介绍慢性肾脏病患者的饮食原则，以及哪些食物该多吃、哪些要少吃。 一、慢性肾脏病患者为何需要"忌口" 肾脏是重要的代谢器官，负责过滤血液中的废物、调节水和电解质平衡。肾脏病变时，代谢和排泄功能 下降，无法及时排出多余的水分、尿素、肌酐、钾、磷等物质。不当饮食，如摄入过多蛋白质或高钾食 物，会加重肾脏负担，导致代谢废物堆积，可能引发高钾血症、高磷血症、水肿、高血压等并发症，进 而加重肾功能损害。例如，过量蛋白质增加尿素生成，过多钾食物可引起心律失常。因此，慢性肾脏病 患者必须根据自身病情，对饮食进行适当"忌口"。 二、这些食物可以多吃，为肾脏"减负" 1.优质低蛋白食物 蛋白质是人体必需的营养素，但慢性肾脏病患者需要控制蛋白质的总摄入量，同时保 证优质蛋白的比例。优质蛋白含有人体必需的氨基酸，易于吸收利用，产生的代谢废 ...

Core Viewpoint - The launch of online first consultation services for pediatric specialties in Beijing marks a significant step towards enhancing accessibility to quality healthcare resources through digital means [1][2][3] Group 1: Online Consultation Services - Beijing Children's Hospital and Capital Institute of Pediatrics have initiated online first consultation services for pediatric growth, nutrition, and skin disease specialties [1] - Starting from January 2026, Beijing will pilot a one-year internet diagnosis and treatment first consultation program, allowing patients to book online consultations with specialists [1] Group 2: Quality and Safety Measures - The pilot program emphasizes quality and safety, requiring first consultation physicians to have at least three years of independent clinical experience and relevant qualifications [1][2] - A dynamic management system will be implemented for first consultation physicians to ensure ongoing competency [1] Group 3: Regulatory and Monitoring Framework - The Beijing Health Commission will utilize an internet diagnosis and treatment regulatory platform to ensure traceability of medical practices, personnel qualifications, and treatment data [2] - In cases where a patient's condition changes or is unsuitable for online consultation, physicians are required to terminate the online service and direct patients to physical medical institutions [2] Group 4: Future Developments in Digital Healthcare - The pilot program is expected to drive the upgrade of the "Internet + Healthcare" ecosystem, with suggestions for developing an electronic prescription transfer platform to facilitate safe prescription flow to nearby pharmacies [3] - The pilot will be evaluated in December 2026, with potential expansion to more specialties and regions, aiming to reduce patient travel and enhance data utilization in healthcare [3]

（来源：南京晨报） 转自：南京晨报 晨报讯（南京晨报/爱南京记者 华琳月 通讯员 胥林花）"机械臂精准到位，止血完成，准备切除病 灶！"1月29日，江苏省肿瘤医院手术室里，泌尿外科主任医师杨杰坐在单孔机器人控制台前，双手轻握 操作杆，双眼紧盯三维高清显示屏，通过5G远程操控着300多公里之外连云港市第二人民医院的手术机 械臂，为74岁的王奶奶实施精准肾脏肿瘤剜除术，历时45分钟。据悉，这是同类手术中的全球首例。 王奶奶因感冒到医院就诊，意外发现左肾上极4厘米×3厘米的占位，考虑肾脏肿瘤。"患者年龄偏大， 体质较弱，对老人家来说手术创伤越小恢复就会越快，单孔机器人手术的微创优势，刚好适合她的病情 需求。"连云港市第二人民医院（连云港市肿瘤医院）是江苏省肿瘤医院的医联体医院，未来也有发展 手术机器人的规划。两院协商后，团队决定采用"5G远程+单孔机器人"的创新模式，患者无需奔波即可 接受省级专家的精准微创手术。 延伸阅读 远程优势：优质医疗资源下沉更便捷 术前，江苏省肿瘤医院派出了全套专家团队"驻守"连云港市第二人民医院，保证手术的安全进行，"患 者的安全永远是放在第一位的。"该院泌尿外科主任医师杨杰表示。"在手 ...

Core Viewpoint - The article highlights the launch of a special action by the Changsha Market Supervision Administration to ensure the safety of medical services and products in rural and urban fringe areas as the Spring Festival approaches [1][5]. Group 1: Special Action Overview - The "Year-End Guardian 100-Day Offensive (2026)" initiative focuses on inspecting medical institutions in rural and urban fringe areas to address issues related to drug and medical device safety [1][5]. - The action aims to identify risks, regulate usage behaviors, and ensure the safety of public medication and medical devices during the festive period [5]. Group 2: Inspection Findings - During inspections, significant violations were found, including the inability of a medical institution to provide purchase certificates for medical devices and the improper storage of drugs on the floor without moisture protection [3]. - A specific electromagnetic wave therapy device was found to be used beyond its expiration date, raising concerns about treatment effectiveness and safety risks [3]. Group 3: Future Actions - The Changsha Market Supervision Administration plans to intensify supervision and follow-up on identified issues to ensure effective rectification and to combat various illegal activities related to drug and medical device usage [5].

近年来，糖尿病、高血压、心脑血管疾病、肿瘤等慢性非传染性疾病(简称慢病)已经成为影响居民寿命和生活质量、增加社会医疗负担的主要因素。如何 进一步做好家门口的慢病管理，还有哪些方面可以提档升级？这些问题，始终萦绕在江苏省政协委员、东南大学医学院内科学系主任孙子林的心头。 一月底的南京，天气正寒。正值省两会召开前夕，扬子晚报/紫牛新闻记者跟随孙子林主任专程来到南京市江宁区禄口街道社区卫生服务中心的基层慢病 筛防中心，与当地居民交流。 结合居民们提出的期盼，孙子林主任表示，围绕基层慢病筛防工作的医保政策再优化，今年也会将相关提案带上两会。"从预防角度看，管好慢病实际上 是为医保节约支出。因此，期待医保能出台更好的支付模式或政策，多措并举，引导和支持慢病'筛防结合、防治一体'体系的建设，助力江苏基层慢病防 控能力提升。" 扬子晚报/紫牛新闻记者吕彦霖 视频于房浩汤清宇 校对陶善工 "血管没问题，搏动有力！"诊室里，孙子林主任仔细查阅禄口街道居民、糖尿病患者赵伯伯的检查报告，并细心询问其糖尿病足的恢复情况。听到专家的 肯定，赵伯伯放下心来，连声称赞这两年社区医院管得好。"医疗这块，真希望更多专科的专家能来，我还有慢阻肺 ...

Group 1: IPO Dynamics - Hunan Mingming Hen Mang Commercial Chain Co., Ltd. officially listed on the Hong Kong Stock Exchange on January 28, 2026, becoming the "first stock of snack retail" in Hong Kong with the stock code "1768" [3] - Mingming Hen Mang issued a total of 15,511,200 H-shares, raising a total of HKD 3.67 billion at an issue price of HKD 236.60 per share, with a subscription rate of 1,899.49 times for public offerings and 44.44 times for international offerings [3][4] - The company has a strong cornerstone investor lineup, including Tencent and Temasek, which subscribed for USD 45 million and USD 45 million respectively, and BlackRock for USD 35 million [4] Group 2: Company Performance - As of September 30, 2025, Mingming Hen Mang operated 19,517 stores across 28 provinces and all tiered cities in China, becoming the first company in the industry to exceed 20,000 stores [5] - The company achieved a GMV of RMB 66.1 billion in the first three quarters of 2025, a year-on-year increase of 74.5%, serving 2.1 billion consumers [5] - The founder and CEO expressed the company's vision to provide affordable snacks and create a joyful experience for consumers [6] Group 3: Aixin Yuanzhi Semiconductor - Aixin Yuanzhi Semiconductor Co., Ltd. plans to list on the Hong Kong Stock Exchange on February 10, 2026, with the stock code "0600" [7] - The company aims to raise up to HKD 2.958 billion by issuing 104,915,200 H-shares at an issue price of HKD 28.20 per share, with a cornerstone investment of USD 185 million [8][9] - Aixin Yuanzhi has become the fifth largest visual edge AI inference chip supplier globally, with a market share of 24.1% in the high-end segment [9][10] Group 4: Zhuozheng Medical - Zhuozheng Medical Holdings Limited plans to list on the Hong Kong Stock Exchange on February 6, 2026, with an IPO target of over HKD 300 million [11][12] - The company has a diverse cornerstone investor base, including notable figures from the medical and technology sectors [12] - Zhuozheng Medical's revenue from 2022 to 2024 showed a compound annual growth rate of 42.2%, with a significant increase in gross profit [13] Group 5: Robotics and Automation - Tianjin Atonmo Robot Co., Ltd. submitted its IPO application to the Hong Kong Stock Exchange on January 28, 2026, focusing on high-precision robots [14][15] - The company has maintained the highest market share in domestic parallel robots for five consecutive years, with a revenue increase of 72.5% in the first three quarters of 2025 [15][16] - Atonmo's products have been applied in over 1,000 scenarios across various industries [14] Group 6: Digital MRO Services - Shanghai Xinyi Linhe Technology Co., Ltd. aims to list on the Hong Kong Stock Exchange, focusing on digital MRO procurement services [20] - The company reported a cumulative transaction volume of approximately RMB 8.5 billion in 2023, with a significant increase in revenue [21][22] - Xinyi Linhe has established partnerships with over 3,000 MRO product manufacturers and suppliers, covering more than 220,000 retail hardware stores [20] Group 7: FA Equipment Procurement - YESMRO Holdings Limited submitted its IPO application to the Hong Kong Stock Exchange, focusing on digital transformation in FA equipment procurement [24][25] - The company has achieved over 81.3% in stock availability and 96.5% in on-time delivery rates, setting industry benchmarks [24] - YESMRO has served over 24,000 different scale automation equipment manufacturers across multiple industries [25] Group 8: Skincare Industry - Shenzhen HBN Technology (Group) Co., Ltd. aims to become the "first stock of true efficacy skincare" in China, with a focus on sustainable brand development [28] - HBN has established itself among the top ten domestic skincare brands in China, with a significant market share in the improvement skincare segment [28][29] - The company reported a revenue of RMB 2.08 billion in 2024, with a notable increase in adjusted net profit [29] Group 9: Automotive Technology - Zhejiang Konghui Automotive Technology Co., Ltd. has initiated its A-share IPO process, focusing on air suspension systems [36][37] - The company has delivered over 1 million air suspension systems and established partnerships with more than 20 mainstream automotive brands [36] - Konghui has successfully entered the supply chain of international luxury automotive brands [37]

Core Viewpoint - The article highlights the launch of online first consultation services in pediatric specialties at Beijing Children's Hospital and Capital Institute of Pediatrics, marking a significant advancement in internet-based healthcare services in China [1] Group 1: Online Consultation Services - The online first consultation services are now available for pediatric growth and development, nutrition, and skin disease specialties [1] - Starting from January 2026, Beijing will initiate a one-year pilot program for internet-based first consultations, approved by the National Health Commission [1] - Patients can make appointments for online first consultations at the two hospitals mentioned [1] Group 2: Transition in Healthcare Services - Previously, internet consultations were primarily limited to follow-ups for common and chronic diseases, requiring patients to provide records from physical medical institutions [1] - The shift from online follow-ups to online first consultations represents a significant step forward in providing quality medical services [1]

Investment Rating - The report maintains a "Buy" rating for the medical services industry [6][10]. Core Insights - The medical and biological sector experienced a decline of 3.31% this week, ranking 22nd among the 31 primary industries in the Shenwan index. The Shanghai and Shenzhen 300 index rose by 0.08%, indicating that the medical sector underperformed by 3.39 percentage points [2][12]. - The newly revised "Regulations on the Implementation of the Drug Administration Law" will take effect on May 15, 2026, aiming to enhance drug research, registration, and production management, thereby fostering innovation in the pharmaceutical industry [5][61]. - The medical services sector's current Price-to-Earnings (PE) ratio is 33.87X, with a Price-to-Book (PB) ratio of 3.43X, reflecting a decrease from the previous week [4][30]. Summary by Sections Industry Performance - The medical services sub-sector closed at 7122.75 points, down 4.15% this week, while the overall medical and biological sector fell by 3.31% [2][24]. - Notable performers in the medical services sector included Tigermed (+4.3%) and Prasis (+2.3%), while underperformers included Bid Pharma (-15.2%) and Haoyuan Pharma (-12.8%) [3][28]. Valuation Metrics - The medical services sector's PE ratio has decreased by 1.43X from the previous week, while the PB ratio has dropped by 0.15X [4][30]. - The maximum and minimum PE ratios over the past year were 41.13X and 28.46X, respectively, while the PB ratios ranged from 4.00X to 2.48X [30][49]. Regulatory Developments - The new drug administration regulations aim to support drug innovation and streamline the drug approval process, including provisions for market exclusivity for certain drugs [5][63]. - The regulations are expected to stimulate the CXO (Contract Research Organization) industry, enhancing demand for preclinical research and clinical trials [9][63]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO companies like WuXi AppTec and Haoyuan Pharma, as well as companies in the consumer healthcare sector like Aier Eye Hospital and Dian Diagnostics, which are expected to see improvements in profitability [10][64].

延庆区卫健委介绍，将继续深化与北医三院、北京中医医院等三甲医院的合作，推出"互联网＋医疗"服 务，提升基层诊疗能力。 来源：北京日报客户端 跨越70多公里的诊疗，依托的是视频通讯系统，可实现影像、病历等资料的实时共享。67岁患者高女士 说："和打视频电话似的，北医三院的医生详细询问了病史，查阅了我的检查报告，给出了治疗方案， 整个过程大概30分钟，还是挺方便的。" 另外，该中心还与北医三院建立急危重症转诊绿色通道。未来，双方还计划推出远程心电诊断等服务。 近日，延庆区首个社区远程会诊中心在延庆镇社区卫生服务中心启用，"直通"北医三院等三甲医院诊 室。 ...